You are here

  • Home
  • Archive
  • Volume 62, Issue 4
  • Benefit of anti-TNFα treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis

Article Text

Article menu
Download PDFPDF
Letter
Benefit of anti-TNFα treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis
  1. P Verschueren1,
  2. F Lensen1,
  3. E Lerut2,
  4. K Claes3,
  5. R De Vos2,
  6. B Van Damme2,
  7. R Westhovens1
  1. 1Department of Rheumatology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
  2. 2Department of Morphology and Molecular Pathology, University Hospitals Leuven, Minderbroedersstraat 12, 3000 Leuven, Belgium
  3. 3Department of Nephrology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
  1. Correspondence to:
    Dr P Verschueren;
    patrick.verschueren{at}uz.kuleuven.ac.be

https://doi.org/10.1136/ard.62.4.368

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Historically, AA amyloidosis accounts for almost half of the deaths among patients with juvenile chronic arthritis, mainly due to complications of end stage renal failure.1 Improved survival has been reported in patients whose underlying inflammatory disorder was brought to remission.2 Tumour necrosis factor (TNFα) blocking agents have been used successfully in the treatment of inflammatory disorders complicated with AA amyloidosis.3–5 We report the effect of TNFα in a case of AA amyloidosis secondary to juvenile spondyloarthropathy.

    CASE REPORT

    A 26 year old man with juvenile, inflammatory bowel disease associated spondyloarthropathy (HLA-B27+) was admitted to our hospital with proteinuria and ankle oedema.

    He received combination therapy with methotrexate, sulfasalazine, methylprednisolone, and naproxen. His blood pressure was 130/80 mmHg. Table 1 shows the results of laboratory tests.

    View this table:
    • In this window
    • In a new window
    Table 1

    Laboratory results at the time of admission

    Ultrasound examination showed an increased bipolar size (130 mm) of both kidneys. A chest x ray examination was normal. A renal …

    View Full Text

    Footnotes

    • P Verschueren and F Lensen contributed equally to this report.